Dr. Sakul led implementation of Pfizer’s diagnostics strategy and currently directs its Diagnostics programs. Under his leadership, FDA approvals were achieved for 7 CDx tests accompanying Pfizer oncology drugs to markets. Hakan serves on the Boards of Progentec Diagnostics and BASH Biotech, and a member of California Governor Newsom’s Precision Medicine Advisory Council. Hakan received his BS and MSc degrees from Ankara University in Turkey, PhD in Quantitative Genetics from the University of Minnesota as a Rotary Foundation Scholar, and conducted postdoctoral studies at the University of California-Davis. He worked in biotech in human genetics and statistical genetics early in his career before moving to pharma. He is the author of over 30 refereed scientific articles as well as many other papers and abstracts. Hakan is keenly interested in molecular diagnostics, liquid biopsy, near-patient testing and related medical technologies to advance Precision Medicine for the improvement of individualized healthcare.
Track Chair: Hakan Sakul, Pfizer